C WorldWide Group Holding A S Invests $15.18 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

C WorldWide Group Holding A S acquired a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 300,000 shares of the company's stock, valued at approximately $15,177,000. C WorldWide Group Holding A S owned 0.21% of Ionis Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. GAMMA Investing LLC purchased a new stake in shares of Ionis Pharmaceuticals during the fourth quarter valued at approximately $26,000. Tennessee Valley Asset Management Partners bought a new position in Ionis Pharmaceuticals during the fourth quarter valued at approximately $34,000. Peoples Bank KS bought a new position in Ionis Pharmaceuticals during the third quarter valued at approximately $39,000. China Universal Asset Management Co. Ltd. lifted its position in Ionis Pharmaceuticals by 95.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,670 shares of the company's stock valued at $166,000 after purchasing an additional 1,795 shares during the period. Finally, Mitchell & Pahl Private Wealth LLC bought a new position in Ionis Pharmaceuticals during the third quarter valued at approximately $210,000. Hedge funds and other institutional investors own 93.86% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on IONS. Royal Bank of Canada increased their price objective on shares of Ionis Pharmaceuticals from $65.00 to $70.00 and gave the company an "outperform" rating in a research report on Friday, January 26th. Wolfe Research upgraded shares of Ionis Pharmaceuticals from a "peer perform" rating to an "outperform" rating and set a $58.00 price objective on the stock in a research report on Wednesday, April 10th. Piper Sandler increased their price objective on shares of Ionis Pharmaceuticals from $62.00 to $63.00 and gave the company an "overweight" rating in a research report on Thursday, February 22nd. StockNews.com upgraded shares of Ionis Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, February 24th. Finally, Bank of America upgraded shares of Ionis Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price target for the stock from $52.00 to $62.00 in a research report on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Ionis Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $56.08.

Insider Transactions at Ionis Pharmaceuticals

In related news, EVP Eric Swayze sold 1,907 shares of the firm's stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $49.56, for a total transaction of $94,510.92. Following the completion of the transaction, the executive vice president now directly owns 34,324 shares of the company's stock, valued at $1,701,097.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Eric Swayze sold 1,907 shares of the firm's stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $49.56, for a total transaction of $94,510.92. Following the completion of the transaction, the executive vice president now directly owns 34,324 shares of the company's stock, valued at $1,701,097.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph Baroldi sold 4,006 shares of the firm's stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total transaction of $166,649.60. Following the transaction, the executive vice president now directly owns 19,631 shares of the company's stock, valued at $816,649.60. The disclosure for this sale can be found here. Insiders sold a total of 42,699 shares of company stock valued at $2,104,091 over the last three months. Corporate insiders own 2.65% of the company's stock.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS traded down $0.25 during midday trading on Friday, reaching $41.59. The stock had a trading volume of 556,093 shares, compared to its average volume of 856,032. The stock has a 50-day moving average of $43.28 and a 200-day moving average of $47.16. The company has a debt-to-equity ratio of 3.18, a quick ratio of 5.83 and a current ratio of 5.90. The company has a market capitalization of $6.06 billion, a price-to-earnings ratio of -16.25 and a beta of 0.39. Ionis Pharmaceuticals, Inc. has a 12-month low of $34.32 and a 12-month high of $54.44.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.72. The firm had revenue of $325.00 million during the quarter, compared to analysts' expectations of $176.01 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative return on equity of 90.29%. The company's revenue for the quarter was up 113.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.37) earnings per share. As a group, research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.69 EPS for the current fiscal year.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.